Pricing By Indication Takes Hold, Despite Hurdles
Indication-based drug pricing is one mechanism for pegging price to value. It will be tough to implement in the US without systemic change, but PBMs have plenty of incentives to make it work.
You may also be interested in...
Policy exempts indications covered by protected classes policy, including cancer treatments.
Overall unit cost in commercial insurance market was up only 2.5% in 2016 despite 11% list increase for brands, PBM's Drug Trend Report concludes; findings could be counterpoint to public and policymaker concerns with drug pricing.
The promise of outcomes-based contracts for biopharmaceuticals has yet to be realized in the US. Although precise numbers are hard to come by, payers and manufacturers agree the field is still nascent. However, they don’t seem to be giving up on the idea.